Pfizer and BioNTech Score Legal Victory Over CureVac in mRNA Patent Dispute

Pfizer and BioNTech have successfully invalidated two of CureVac's patents at London's High Court. The dispute revolves around mRNA technology, crucial for Pfizer's COVID-19 vaccine. This ruling is part of a broader international legal conflict involving additional cases in the US and Germany.

In a recent ruling at London's High Court, Pfizer and its German partner BioNTech successfully invalidated two patents held by CureVac. This legal victory is a significant development in the ongoing global patent dispute involving messenger RNA (mRNA) technology.

The case, initially filed in September 2022, is part of a broader litigation effort by Pfizer and BioNTech to protect their interests related to mRNA technology, which is pivotal to their COVID-19 vaccine. This particular ruling pertains to the UK segment of their international legal battle with CureVac, which also has active disputes in the United States and Germany.

Additionally, Pfizer and BioNTech are engaged in a separate legal contest with Moderna concerning their respective COVID-19 vaccines. In July, London's High Court upheld the validity of one of Moderna's patents, suggesting Pfizer's Comirnaty vaccine infringed upon it. Pfizer is appealing this decision.

(With inputs from agencies.)